New therapeutic targets and drugs for the treatment of chronic hepatitis B

Seminars in Liver Disease

Volumn 33, Issue 2, 2013, Pages 130-137

  Fletcher, Simon P ^a   Delaney, William E ^a  

^a Gilead Sciences ^*  (United States)

Author keywords

antiviral therapy; chronic hepatitis B; hepatitis B virus (HBV); immunotherapy; treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BMS 936559; CIRCULAR DNA; DACLIZUMAB; ENTECAVIR; GENHEVAC; GS 9620; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; LAMIVUDINE; MESSENGER RNA; MYRCLUDEX; NIVOLUMAB; PEGINTERFERON ALPHA; RECOMBINANT INTERLEUKIN 7; SIPULEUCEL T; TARMOGEN; TELBIVUDINE; TENOFOVIR; THYMOSIN ALPHA1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADD ON THERAPY; ADVANCED CANCER; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EPIGENETICS; HEPATITIS B; HUMAN; INNATE IMMUNITY; LIVER; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; RNA STABILITY; SEROCONVERSION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84878882103     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1345713     Document Type: Article

References (87)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat: 2004; 11 2 97 107 (Pubitemid 38365759)
2. Kwon H., Lok A. S. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol: 2011; 8 5 275 284
3. Papatheodoridis G., et al. European Association for the Study of the Liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol: 2012; 57 1 167 185
4. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet: 2013; 381 9865 468 475
5. Buster E. H., Flink H. J., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology: 2008; 135 2 459 467
6. Seeger C., Mason W. S. Hepatitis B virus biology. Microbiol Mol Biol Rev: 2000; 64 1 51 68 (Pubitemid 30143840)
7. Seeger C., Zoulim F., Mason W. S. Hepadnaviruses. In: Knipe D. M., Howley P. M., eds. Fields Virology (Vol. 2). Philadelphia, PA Lippincott Williams & Wilkins: 2007; 2977 3030
8. Werle-Lapostolle B., Bowden S., Locarnini S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology: 2004; 126 7 1750 1758 (Pubitemid 38736340)
9. Gripon P., Cannie I., Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol: 2005; 79 3 1613 1622 (Pubitemid 40459108)
10. Petersen J., Dandri M., Mier W., et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol: 2008; 26 3 335 341 (Pubitemid 351355128)
11. Volz T., Allweiss L., M Barek MB, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol: 2012
12. Yan H., Zhong G., Xu G., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human. hepatitis B and D virus. eLife 2012;1:e00049
13. Haefeli W. E., Blank A., Mikus G., Mier W., Alexandrov A., Urban S. Successful first administration of Myrcludex B, a first-in-class hepatitis B and D virus entry inhibitor, in humans. Hepatology: 2012; 56 372A
14. Cai D., Mills C., Yu W., et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother: 2012; 56 8 4277 4288
15. Cradick T. J., Keck K., Bradshaw S., Jamieson A. C., McCaffrey A. P. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther: 2010; 18 5 947 954
16. Händel E. M., Gellhaus K., Khan K., et al. Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. Hum Gene Ther: 2012; 23 3 321 329
17. Zimmerman K. A., Fischer K. P., Joyce M. A., Tyrrell D. L. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol: 2008; 82 16 8013 8021
18. Zhao X., Zhao Z., Guo J., et al. Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line. J Biomol Screen: 2013; 18 4 378 387
19. Belloni L., Allweiss L., Guerrieri F., et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest: 2012; 122 2 529 537
20. Nash K. L., Alexander G. J., Lever A. M. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J Viral Hepat: 2005; 12 4 346 356 (Pubitemid 40961473)
21. Welch P. J., Tritz R., Yei S., Barber J., Yu M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther: 1997; 4 7 736 743 (Pubitemid 27343136)
22. zu Putlitz J., Wieland S., Blum H. E., Wands J. R. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology: 1998; 115 3 702 713 (Pubitemid 28397306)
23. McCaffrey A. P., Nakai H., Pandey K., et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol: 2003; 21 6 639 644 (Pubitemid 36638090)
24. Morrissey D. V., Lockridge J. A., Shaw L., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol: 2005; 23 8 1002 1007 (Pubitemid 41114035)
25. Klein C., Bock C. T., Wedemeyer H., et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology: 2003; 125 1 9 18 (Pubitemid 36799102)
26. Keaney J., Campbell M., Humphries P. From RNA interference technology to effective therapy: how far have we come and how far to go? Ther Deliv: 2011; 2 11 1395 1406
27. Deres K., Schröder C. H., Paessens A., et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science: 2003; 299 5608 893 896 (Pubitemid 36182448)
28. Wang X. Y., Wei Z. M., Wu G. Y., et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther: 2012; 17 5 793 803
29. Delaney W. E. IV, Edwards R., Colledge D., et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother: 2002; 46 9 3057 3060
30. Feld J. J., Colledge D., Sozzi V., Edwards R., Littlejohn M., Locarnini S. A. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res: 2007; 76 2 168 177 (Pubitemid 47410321)
31. Wang P., Naduthambi D., Mosley R. T., et al. Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs. Bioorg Med Chem Lett: 2011; 21 15 4642 4647
32. Billioud G., Pichoud C., Puerstinger G., Neyts J., Zoulim F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res: 2011; 92 2 271 276
33. Katen S. P., Chirapu S. R., Finn M. G., Zlotnick A. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem Biol: 2010; 5 12 1125 1136
34. Stray S. J., Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit: 2006; 19 6 542 548 (Pubitemid 46024897)
35. Weber O., Schlemmer K. H., Hartmann E., et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res: 2002; 54 2 69 78 (Pubitemid 34327685)
36. Brezillon N., Brunelle M. N., Massinet H., et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS ONE: 2011; 6 12 e25096
37. Xu Y., Hu Y., Shi B., et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol: 2009; 46 13 2640 2646
38. Woltman A. M., Op den Brouw M. L., Biesta P. J., Shi C. C., Janssen H. L. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE: 2011; 6 1 e15324
39. Mahtab M. A., Bazinet M., Vaillant A. REP 9AC': A second generation HBsAg release inhibitor with improved tolerability. Hepatology: 2012; 56 401A 402A
40. Patient R., Hourioux C., Roingeard P. Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol: 2009; 11 11 1561 1570
41. Block T. M., Lu X., Platt F. M., et al. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A: 1994; 91 6 2235 2239
42. Block T. M., Lu X., Mehta A. S., et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med: 1998; 4 5 610 614 (Pubitemid 28237362)
43. Dougherty A. M., Guo H., Westby G., et al. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother: 2007; 51 12 4427 4437 (Pubitemid 350209899)
44. Yu W., Goddard C., Clearfield E., et al. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem: 2011; 54 16 5660 5670
45. Bertoletti A., Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut: 2012; 61 12 1754 1764
46. Ilan Y., Nagler A., Adler R., Tur-Kaspa R., Slavin S., Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology: 1993; 104 6 1818 1821 (Pubitemid 23235477)
47. Lau G. K., Suri D., Liang R., et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology: 2002; 122 3 614 624 (Pubitemid 34173812)
48. Penna A., Laccabue D., Libri I., et al. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol: 2012; 56 6 1239 1246
49. Micco L., Peppa D., Loggi E., et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol: 2013; 58 2 225 233
50. Byrnes-Blake K. A., Pederson S., Klucher K. M., et al. Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. J Interferon Cytokine Res: 2012; 32 5 198 206
51. Witte K., Gruetz G., Volk H. D., et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun: 2009; 10 8 702 714
52. Chan H., et al. Peginterferon lambda, a new potential therapeutic option for the treatment of chronic hepatitis B: a phase 2B comparison with peginterferon alfa in patients with HBeAg- positive disease. Hepatology: 2012; 56 1525A 1526A
53. Ji C., Sastry K. S., Tiefenthaler G., et al. Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology: 2012; 56 6 2027 2038
54. Elsaesser H., Sauer K., Brooks D. G. IL-21 is required to control chronic viral infection. Science: 2009; 324 5934 1569 1572
55. Fröhlich A., Kisielow J., Schmitz I., et al. IL-21R on T-cells is critical for sustained functionality and control of chronic viral infection. Science: 2009; 324 5934 1576 1580
56. Yi J. S., Du M., Zajac A. J. A vital role for interleukin-21 in the control of a chronic viral infection. Science: 2009; 324 5934 1572 1576
57. Pellegrini M., Calzascia T., Toe J. G., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell: 2011; 144 4 601 613
58. Nanjappa S. G., Kim E. H., Suresh M. Immunotherapeutic effects of IL-7 during a chronic viral infection in mice. Blood: 2011; 117 19 5123 5132
59. Publicover J., Goodsell A., Nishimura S., et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest: 2011; 121 3 1154 1162
60. Kennedy P. T., Sandalova E., Jo J., et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology: 2012; 143 3 637 645
61. Hashmi M. H., Van Veldhuizen P. J. Interleukin-21: updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther: 2010; 10 5 807 817
62. Mackall C. L., Fry T. J., Gress R. E. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol: 2011; 11 5 330 342
63. Zhang X., Kraft A., Broering R., Schlaak J. F., Dittmer U., Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov: 2012; 7 7 597 611
64. Menne S., et al. Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J Hepatol: 2011; 54 S441
65. Lanford R. E., Guerra B., Chavez D., et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanze. Gastroenterology: 2013; Feb 13 [Epub ahead of print]
66. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol: 2005; 5 3 215 229 (Pubitemid 40364823)
67. Boni C., Penna A., Bertoletti A., et al. Transient restoration of anti-viral T-cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol: 2003; 39 4 595 605 (Pubitemid 37204661)
68. Boni C., Laccabue D., Lampertico P., et al. Restored function of HBV-specific T-cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology: 2012; 143 4 963 973
69. Xu D. Z., Zhao K., Guo L. M., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE: 2008; 3 7 e2565
70. Bertoletti A., Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol: 2009; 3 5 561 569
71. Kemmler C. B., et al. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S, and core antigens generate antigen specific T-cell responses in immune samples from healthy and chronic HBV donors. Hepatology: 2012; 56 373A 374A
72. Guo Z., et al. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S and core antigens generate antigen specific T-cell responses and tumor protection in mice. Hepatology: 2012; 56 375A 376A
73. Crawford A., Wherry E. J. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr Opin Immunol: 2009; 21 2 179 186
74. Fisicaro P., Valdatta C., Massari M., et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T-cells against HBV, but not HCV. Gastroenterology: 2012; 143 6 1576 1585, e4
75. Fisicaro P., Valdatta C., Massari M., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology: 2010; 138 2 682 693, e1-e4
76. Topalian S. L., Hodi F. S., Brahmer J. R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med: 2012; 366 26 2443 2454
77. Brahmer J. R., Tykodi S. S., Chow L. Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med: 2012; 366 26 2455 2465
78. Hodi F. S., O'Day S. J., McDermott D. F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med: 2010; 363 8 711 723
79. Brooks D. G., Trifilo M. J., Edelmann K. H., Teyton L., McGavern D. B., Oldstone M. B. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med: 2006; 12 11 1301 1309 (Pubitemid 44706933)
80. Ejrnaes M., Filippi C. M., Martinic M. M., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med: 2006; 203 11 2461 2472 (Pubitemid 44664616)
81. Tinoco R., Alcalde V., Yang Y., Sauer K., Zuniga E. I. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T-cell deletion and viral persistence in vivo. Immunity: 2009; 31 1 145 157
82. Peppa D., Micco L., Javaid A., et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog: 2010; 6 12 e1001227
83. Akhurst R. J., Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov: 2012; 11 10 790 811
84. Manigold T., Racanelli V. T-cell regulation by CD4 regulatory T-cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis: 2007; 7 12 804 813 (Pubitemid 350152043)
85. Rech A. J., Mick R., Martin S., et al. CD25 blockade depletes and selectively reprograms regulatory T-cells in concert with immunotherapy in cancer patients. Sci Transl Med: 2012; 4 134 34ra62
86. Sutmuller R. P., Morgan M. E., Netea M. G., Grauer O., Adema G. J. Toll-like receptors on regulatory T-cells: expanding immune regulation. Trends Immunol: 2006; 27 8 387 393 (Pubitemid 44038663)
87. Otano I., Suarez L., Dotor J., et al. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology: 2012; 56 2 474 483